Adsorption may notably contribute to the removal of uremic toxins and to the efficiency of hemodialysis. We examined different uncoated stationary matrixes, charcoals and synthetic resins to establish their adsorptive capacities in relation to low (urea, creatinine) and high molecular weight (β2-microglobulin, myoglobin) compounds in in vitro conditions (steady state and flow-through) using isotonic solutions or uremic ultrafiltrate. Trace metal, particle release analyses and scanning electron microscopy of different adsorbents were performed. Dynamic flow-distribution studies were made using 99Technetium and analysing the different regions of interest by single head γ-camera. We show that adsorbents may differ greatly as to their adsorptive capacity depending on flow rate, nature, and total mass of the compounds to be removed from the ultrafiltrate. These studies suggest a methodological approach for screening stationary matrixes for possible application in hemodialysis.
DhondtA.M., VanholderR., van BiesenW., LameireN.. The removal of uremic toxins. Kidney Int2000; 58(suppl. 76): S47–59.
2.
JaradatM.I., MoeS.M.. Effect of hemodialysis membranes on β2-microglobulin amyloidosis. Semin Dial2001; 14: 107–12.
3.
FujimoriA., NaitoH., MiyazakiT.. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Int J Artif Organs1998; 22: 1014–7.
4.
PascualM., SchifferliJ.A.. Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int1993; 43: 903–11.
5.
RoncoC., TettaC., LupiA.Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med1995; 23: 99–107.
6.
GhezziPM, FrigatoG., FantiniG.F.Theoretical model and first clinical results of the paired filtration-dialysis (PFD). Life Support Syst1983; 1(suppl. 1): S271–4.
7.
GhezziP.M., BotellaJ., SartorisA.M., GervasioR., DiezC.. Use of the ultrafiltrate obtained in two-chamber (PFD) hemodiafiltration as replacement fluid. Experimental ex vivo and in vitro study. Int J Artif Organs1991; 14: 327–34.
8.
La GrecaG., BrendolanA., GhezziPM.The concept of sorbent in hemodialysis. Int J Artif Organs1998; 21: 303–8.
9.
De FranciscoA.L.M., BotellaJ., EscalladaR.Haemodiafiltration with adsorbent-regenerated ultrafiltrate as replacement fluid: a multicenter study. Nephrol Dial Transplant1997; 12: 528–34.
10.
De FranciscoA.L.M., GhezziP.M., BrendolanA.Hemodiafiltration with on line regeneration of the ultrafiltrate. Kidney Int2000; 58(suppl. 76): S66–71.
11.
Charcoal, activated. In: European Pharmacopoeia, 3rd ed.1997 (suppl 2000): 524–525A.
12.
AAMI. Standards and recommended practices, vol. 3, Arlington, VA: Association for the Advancement of Medical Instrumentation.1992; RD5.
13.
Hemofiltration, solution for. In: European Pharmacopoeia. 3rd ed. 1997: 925–7.
14.
British Pharmacopoeia, 1993, Appendix XIII, A163.
15.
Physical Tests/Particulate Matter in Injections/Large-volume injections for single-dose infusion. In: United States Pharmacopoeia XXI Ed.1985.
16.
Soluzioni perfusionali, per dialisi, anticoagulanti (Soluzioni parenterali di grande volume). In. Farmacopea Ufficiale Italiana X Ed, anno1996 5.1. F.U. 1
17.
ShaldonS., BeauM.C., ClaretG.Sorbent regeneration of ultrafiltrate as a long-term treatment of end-stage renal failure. Int J Artif Organs1978; 4: 343–7.
18.
TettaC., CavaillonJ.M., SchulzeM.Removal of cytokines and activated complements in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant1998; 13: 1458–64.
19.
CerulliN., PolitiL., D'AngeloA.R., ScandurraR.. A purification method by uncoated charcoal. Adv Exp Med Biol1987; 223: 193–6.
20.
RichterR., Schulz-KnappeP., SchraderM.Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromat B Biomed Sci Appl1999; 726: 25–35.
21.
LindnerA., VanholderR., De SmetR.HPLC fractions of human uremic plasma inhibit the red blood cell membrane calcium pump. Kidney Int1997; 51: 1042–52.
22.
ThylenP., FernvikE., HaegerstrandA., LundahlJ., JacobsonS.. Dialysis-induced serum factors inhibit adherence of monocytes and granulocytes to adult human endothelial cellsAm J Kidney Dis1997; 29: 78–85.
23.
VanholderR., De SmetR., JacobsV.Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant1994; 9: 1271–8.
24.
AndoM., GafvelsM., BergstroemJ., LindholmB., LunkkvistI.. Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int1997; 51: 785–92.
PolittiL., CerulliN., D'AngeloA.R., ScadurraR.. Perfusion of uremic blood ultrafiltrate on uncoated charcoal. Int J Artif Organs1989; 13: 246–51.
27.
LameireN.H., De VrieseA.. Adsorption techniques and the use of sorbents. In: RoncoC., WinchesterJ.F., eds. Dialysis, dialyzers and sorbents. Where are we going?Contrib Nephrol2001; 133: 140–53.
28.
ProvostM.C., MeyersC.M.. New technologies for patients with end-stage renal disease: the U.S. regulatory perspective. In: RoncoC., WinchesterJ F., eds. Dialysis, dialyzers and sorbents. Where are we going?Contrib Nephrol2001; 133: 10–22.
